LivaNova Brand Guidelines: Sorin’s 1956 Nuclear Lab, Houston’s Cyberonics & a 2015 Merger

A nuclear research company that turned to the heart.

LivaNova’s Italian half began as a nuclear research company. Sorin stands for Società Ricerche Impianti Nucleari, and Italian Wikipedia says it was founded at Saluggia, in Piedmont, in 1956, with Montecatini and Fiat as shareholders; English Wikipedia names Fiat and Montedison, Italy’s two largest industrial groups. Its Avogadro research reactor was inaugurated at the end of 1959, Italian Wikipedia says. English Wikipedia describes the early Sorin as a research company with an experimental reactor for materials research, meant to serve as the “brain” of the two groups’ nuclear energy plans, with no ambitions yet in medicine.

When Italy nationalised its electricity industry in the 1960s, Sorin changed course. Italian Wikipedia says it began making mitral valves and cardiac pacemakers and took the name Sorin Biomedica; English Wikipedia says the conversion made it profitable within three years. It listed on the Milan stock exchange in 1985, and in 1986 Fiat’s stake passed to the chemicals and fibres group SNIA BPD.

Acquisitions built it into an international heart-surgery business. In 1992 Sorin Biomedica bought the cardiovascular division of Pfizer, which traded as Shiley, and with it Dideco of Mirandola, a maker of oxygenators and extracorporeal circulation systems, and Stöckert of Munich, a maker of heart-lung machines. The group added Cobe Cardiovascular of Denver in 1999, the Paris pacemaker and defibrillator maker Ela Medical in 2001, and the mechanical valve maker CarboMedics of Austin, with the Canadian tissue-valve maker Mitroflow, in 2003. Its own Carbofilm coating was used on its valves and on the Carbostent coronary stent, English Wikipedia says.

In 2000 Sorin Biomedica was absorbed into SNIA. In December 2003 a new Sorin Group S.p.A. was created to receive SNIA’s medical technology business, and it was listed in Milan from January 2004, Italian Wikipedia says. Besides heart surgery, the group then had a renal care side: Italian Wikipedia lists Bellco of Mirandola, a maker of haemodialysis equipment, and Soludia of Toulouse, a maker of dialysis solutions, among its former companies.

Cyberonics, and a new name.

The American half was Cyberonics, founded in Houston in 1987, English Wikipedia says. Its field was vagus nerve stimulation, the therapy LivaNova sells today as VNS Therapy for drug-resistant epilepsy and difficult-to-treat depression; LivaNova says it has more than 25 years of experience with it.

On 26 February 2015 Sorin Group announced that it would merge with Cyberonics under a new holding company based in the United Kingdom. On 25 June 2015 the two companies revealed the name, LivaNova, which Italian Wikipedia says combines the English word “live” with the Latin “nova,” meaning new. The merger was completed on 19 October 2015, when LivaNova shares began trading in New York on Nasdaq, and in London, under the symbol LIVN, and Sorin left the Milan exchange.

LivaNova started with three divisions: cardiac surgery, run from Mirandola; neuromodulation, run from Houston; and cardiac rhythm management, run from Clamart in France, according to Italian Wikipedia. It soon narrowed that mix. In 2018 it sold the cardiac rhythm business to MicroPort Scientific Corporation, and in 2020 it sold its heart valve business to the investment firm Gyrus Capital, where it became a new company, Corcym. Along the way it bought ImThera Medical, announced in December 2017, and in 2022 the Pittsburgh lung-support company ALung Technologies, English Wikipedia says; in 2020 it set up Epsy Health, a digital unit for people living with epilepsy.

Vladimir Makatsaria became chief executive on 1 March 2024, English Wikipedia says.

Heart devices and documentation.

Cardiovascular device makers sell to a narrow audience: interventional cardiologists, electrophysiologists, cardiac surgeons, hospital buyers and regulators. Their visual language follows from that. A heart valve, a stent or a pacemaker is small, precise and usually hidden inside the body once it is in use, so the product photograph does much of the work. Valves, stents and leads tend to be shot in close-up on white or pale grey, lit to show struts, mesh and metal edges, with the device itself as the only subject.

The second register is the catheterisation laboratory. Brochures, websites and congress stands return again and again to the same scene: a patient table, a C-arm X-ray system arched over it, banks of monitors showing angiograms or mapping images, and clinicians in scrubs, lead aprons and caps. These pictures place the device in the room where it is used, without showing the patient’s body in detail.

Between the two sits illustration. Cutaway hearts, cross-sections of arteries and simplified diagrams of the conduction system explain where a valve sits, how a stent opens or how a lead reaches the heart. They are often rendered in reds and soft pinks against white, with the brand’s own colour kept for the device, the arrows and the type. Much of the copy is technical, built around product names, trial names and regulatory approvals as the companies state them.

Much of the category’s public life happens at medical congresses. TCT in the United States, EuroPCR in Paris and the ESC Congress of the European Society of Cardiology bring makers, clinicians and trade press together each year, and companies use them to show new devices and announce study results. The makers in this guide range from family-owned German engineering firms to Chinese groups with several listed subsidiaries, and their identities reflect that range more than any shared house style.

Perfusion systems and nerve stimulation.

Today LivaNova PLC is registered in England and Wales, its website says, and English Wikipedia describes it as a UK-domiciled company with operational headquarters in the United States. The website groups its work into three areas — cardiopulmonary, drug-resistant epilepsy and difficult-to-treat depression — and names the Essenz Perfusion System and VNS Therapy as lead products. It says it has more than 50 years of cardiopulmonary experience and more than 3,000 employees; those are the company’s own figures.

The Sorin spin-off also brought a long legal dispute. SNIA’s former chemicals subsidiary Caffaro left contaminated land at Brescia, Torviscosa and Colleferro, and the Italian state sought clean-up costs from Sorin, and later LivaNova, as the beneficiary of SNIA’s 2003 demerger, Il Post reported in October 2024. A Milan court rejected the claim in 2016; the Court of Appeal in Milan reversed that in 2019, holding LivaNova jointly liable within the limits of the assets it received, and set the amount in 2021. LivaNova appealed to Italy’s Court of Cassation, which referred a question on demerger law to the Court of Justice of the European Union; that court ruled on 29 July 2024. In February 2025 Il Giorno reported a hearing at the Court of Cassation, with LivaNova saying it was still awaiting a decision.

For a design guide, LivaNova shows how a merged company can take an invented name that belongs to neither parent, while the older names — Sorin, Cyberonics, Dideco — stay in the record. Compare MicroPort, which took over its rhythm business, and Medtronic, another heart-device maker. For this guide we use a deep teal, sage and a pale mist with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep LivaNova’s identity on hand — save it to a board in the Made Good inspiration library.